JPRN-UMIN000013257尚未招募未知
Phase I clinical trial of WT1 peptide-based vaccine combined with Temozoromide for pediatric patients with malignant glioma. - Phase I clinical trial of WT1 peptide-based vaccine combined with Temozoromide for pediatric patients with malignant glioma
Osaka University Graduate School of Medicine Pediatrics0 个研究点目标入组 18 人开始时间: 2014年2月26日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 16years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.There is deep-seated active infection. 2.There are severe complications including malignant hypertention, cardiac failure, liver cirrhosis, severe DM, severe lung fiblosis, active interstitial pneumonitis. 3.Patients who have complications that are considered inappropriate for the trial. 4.There are other malignancies. 5.There are hematopoietic stem cell disorders such as MDS. 6.Post allogeneic hematopoietic stem cell transplantation 7.Responsible doctors judged the patient inappropriate for the trial
研究者
相似试验
已完成
1 期
Phase I clinical trial of WT1 peptide-based vaccine for the HLA-A*0201 positive patients with malignant tumors.Malignant solid tumors, Malignant lymphoma, Multiple Myeloma, Acute leukemiaJPRN-UMIN000000933Department of Cancer immunotherapy, Osaka University Medical School10
已完成
1 期
Phase I clinical trial of WT1 peptide-based vaccine combined with Temozoromide for patients with malignant glioma.Malignant GliomaJPRN-UMIN000003504Department of Cancer immunotherapy, Osaka University Graduate School of Medicine3
已完成
1 期
Phase I clinical trial of WT1 peptide vaccine therapy for pediatric cancersPediatric cancersJPRN-UMIN000011030Shinshu University15
已完成
1 期
Phase I/II clinical trial of WT1 peptide vaccine therapy for lung, breast, pancreas, stomach, and colorectal cancerung, breast, pancreas, stomach, and colorectal cancerJPRN-UMIN000011029Shinshu University50
已完成
不适用
Phase I/II clinical trial of WT1 peptide vaccine for the children with malignanciesJPRN-UMIN000002990Osaka Medical Center and Research Institute for Maternal and Child Health20